CDNA vs FATE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 20, 2026

CDNA

30.1
AI Score
VS
FATE Wins

FATE

57.2
AI Score

Investment Advisor Scores

CDNA

30score
Recommendation
SELL

FATE

57score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CDNA FATE Winner
Revenue 249.65M 3.38M CDNA
Net Income 113.44M -61.37M CDNA
Net Margin 45.4% -1815.2% CDNA
Operating Income 114.42M -64.13M CDNA
ROE 26.7% -40.0% CDNA
ROA 21.3% -23.6% CDNA
Total Assets 532.99M 260.10M CDNA
Cash 373.64M 32.43M CDNA
Current Ratio 4.58 4.85 FATE
Free Cash Flow 29.26M -54.58M CDNA

Relative Price Performance (Last 90 Days)

CDNA 1M: +36.1% · 3M: +128.3% FATE 1M: -3.3% · 3M: -19.5%

Current Technical Phase

CDNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (24.8% over 20 days), RSI 81

RSI (14): 80.8 · Price: $66.66

FATE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -5.0%), weak momentum, RSI 44

RSI (14): 44.1 · Price: $2.35

Fundamentals Snapshot

Metric CDNA FATE
Market Cap — —
Forward P/E 51.3 -2.4
Trailing P/E 30.8 —
Revenue (TTM) — —
Revenue Growth 0.5% 0.1%
Gross Margin 0.7% -12.0%
Operating Margin 0.0% -15.0%
EPS 2.11 -1.05
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, FATE is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.